Trial Information
Inclusion Criteria:
- potential breast cancer
- patients who have early stages of breast cancer prior to surgery potential prostate
cancer lung cancer colon cancer
Exclusion Criteria:
- 1) Patients will be excluded from enrollment if they have severe liver disease (ALT
three times the upper limit of normal). Patients will also be excluded who have taken
aspirin or COX inhibitors within 48 hours of surgery. 2) Patients will be excluded if
a pathologic diagnosis is already available,from a previous needle biopsy
(coordinator will remain blinded). 3) Patients will be excluded have received
pre-procedure chemotherapy or radiotherapy
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Estimate predictive values for each type of cancer.
Outcome Description:
The primary outcome for Specific Aim 1 will be the area under the ROC curve and 95% confidence interval for each metabolite.
Outcome Time Frame:
Day 1
Safety Issue:
No
Principal Investigator
Daniel Sessler, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
The Cleveland Clinic
Authority:
United States: Food and Drug Administration
Study ID:
12-306
NCT ID:
NCT01692951
Start Date:
August 2012
Completion Date:
August 2014
Related Keywords:
- Prostate Cancer
- Breast Cancer
- Colon Cancer
- Lung Cancer
- Breast Neoplasms
- Colonic Neoplasms
- Lung Neoplasms
- Prostatic Neoplasms
Name | Location |
Cleveland Clinic |
Cleveland, Ohio 44195 |